Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)
Status:
Terminated
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
- Fimasartan will be more beneficial in stabilizing the plaque vulnerability compared to
control group in deferred coronary lesions.
- Fimasartan will be more beneficial in reducing total plaque volume compared to control
group in deferred coronary lesions.
- Fimasartan will be more beneficial in reducing functional impairment of stenotic lesions
(assessed by FFR:Fractional Flow Reserve) in deferred coronary lesions.
Phase:
Phase 4
Details
Lead Sponsor:
Seung-Jung Park
Collaborators:
Boryung Pharmaceutical Co., Ltd CardioVascular Research Foundation, Korea